Editas Medicine, Inc. — 2019 Form 10-K Summary
Business context and reporting period
Annual report for the fiscal year ended December 31, 2019; quarterly figures are also presented for Q4. Editas is a clinical-stage genome-editing company developing CRISPR-based medicines. EDIT-101, its LCA10 candidate, entered a Phase 1/2 trial in 2019; other programs were preclinical or in research. The company had no product-sale revenue.
Financial performance and liquidity
| Metric | FY 2019 | FY 2018 |
|---|---|---|
| Collaboration and research revenue | $20.5 million | $31.9 million |
| Research and development expense | $96.9 million | $90.7 million |
| General and administrative expense | $64.6 million | $55.0 million |
| Operating loss | $140.9 million | $113.7 million |
| Net loss | $133.7 million | $110.0 million |
| Net loss per share, basic and diluted | $2.68 | $2.33 |
| Net cash used in operating activities | $40.7 million | $45.7 million |
At year-end, cash, cash equivalents and marketable securities totaled $457.1 million; working capital was $403.9 million and total assets were $508.9 million. Management expected available funds and interest income to cover operating and capital requirements for at least 24 months after the filing. The company reported $29.1 million of operating lease liabilities; it had no construction financing lease obligation remaining. No product gross margin was reported, and margins are not meaningful for a business without product sales. The company reported an accumulated deficit of $549.2 million.
Material changes versus comparable periods
- Annual collaboration revenue fell 36%, principally reflecting lower Allergan revenue recognition and a one-time $3.9 million out-license payment recognized in 2018.
- Annual operating expenses rose 11%, while net loss widened 22%. R&D costs increased 7% and G&A costs increased 17%.
- Q4 2019 revenue was $12.3 million versus $6.1 million in Q4 2018; Q4 net loss was $37.8 million versus $25.1 million. Q4 operating expenses increased to $51.7 million from $32.4 million.
- Operating cash use improved by $5.0 million year over year. Financing provided $131.8 million in 2019, including $116.3 million net from at-the-market stock offerings, increasing shares outstanding to 54.4 million from 48.8 million.
- A November 2019 Juno agreement amendment generated a $70.0 million upfront payment; $96.3 million remained deferred at year-end. Revenue recognition therefore does not equate to cash received in the same period.
Outlook, risks and unusual items
- Management expected losses and expenses to continue and did not expect profitability in 2020 or the foreseeable future. Additional capital may be needed; financing could dilute shareholders or require concessions on technology or product rights.
- Management expected to announce first EDIT-101 patient dosing by the end of Q1 2020 and planned to enroll about 18 patients. The company aimed to file an IND for EDIT-301 in sickle cell disease by the end of 2020. These are forward-looking targets, not achieved results.
- EDIT-101 development and U.S. profits and losses are shared with Allergan under a co-development arrangement. Allergan retains control of development and commercialization decisions for the program.
- Key risks include clinical and safety uncertainty for genome editing, off-target effects, small patient populations and trial enrollment, regulatory uncertainty, manufacturing dependence on third parties, competition, and reimbursement/pricing uncertainty.
- CRISPR intellectual-property rights face significant disputes. The filing describes a second U.S. interference proceeding involving in-licensed patents and European patent oppositions; several European patents had been revoked, with appeals pending or withdrawn. Patent-related reimbursement costs were substantial, approximately $14 million in 2019.
- Potential milestone, success, sublicense and royalty obligations to licensors are contingent and are not included in the disclosed contractual-obligations table. Scheduled operating lease payments totaled $35.1 million.
- The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting as of December 31, 2019.
Important facts for investors to verify
- Whether EDIT-101 dosing began on the stated timetable and what safety, tolerability and efficacy data subsequently showed.
- Whether EDIT-301 met its IND-filing target and how its development schedule and costs evolved.
- Cash runway assumptions, subsequent cash use, financing activity and the dilution from equity issuance.
- How deferred collaboration revenue is recognized, and whether Juno or Allergan options, milestones or other payments are earned.
- Developments in U.S. and European CRISPR patent proceedings and the resulting impact on exclusivity, licensing costs and program rights.